NAS:CEMI (USA)

Chembio Diagnostics Inc

$ 5.86 -0.25 (-4.09%)
Volume: 38,597 Avg Vol (1m): 64,308
Market Cap $: 100.59 Mil Enterprise Value $: 93.57 Mil
P/E (TTM): 0.00 P/B: 3.25
Earnings Power Value -3.19
Net Current Asset Value 0.74
Tangible Book 1.31
Projected FCF -1.74
Median P/S Value 3.64
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 21.06
Cash-To-Debt ranked higher than
60.92% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
CEMI: 21.06
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 22.4, Max: 10000
Current: 21.06
0.02
10000
Equity-to-Asset 0.68
Equity-to-Asset ranked higher than
76.15% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
CEMI: 0.68
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.07, Med: 0.72, Max: 0.87
Current: 0.68
-2.07
0.87
Debt-to-Equity 0.01
Debt-to-Equity ranked higher than
97.56% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
CEMI: 0.01
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -682.5, Med: 0.02, Max: 0.42
Current: 0.01
-682.5
0.42
Debt-to-EBITDA -0.04
Debt-to-EBITDA ranked lower than
100.00% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
CEMI: -0.04
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.06, Med: 0.08, Max: 1.41
Current: -0.04
-0.06
1.41
Piotroski F-Score 1
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.76
DISTRESS
GREY
SAFE
Beneish M-Score -0.46
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -56.6%
WACC 13.34%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -28.51
Operating Margin ranked lower than
62.81% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
CEMI: -28.51
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -42.38, Med: -1.66, Max: 15.41
Current: -28.51
-42.38
15.41
Net Margin % -29.51
Net Margin ranked lower than
62.66% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
CEMI: -29.51
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -74.69, Med: -1.16, Max: 32.02
Current: -29.51
-74.69
32.02
ROE % -38.62
ROE ranked lower than
67.36% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
CEMI: -38.62
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -76.64, Med: -1.29, Max: 67.84
Current: -38.62
-76.64
67.84
ROA % -29.06
ROA ranked lower than
67.18% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
CEMI: -29.06
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -64.49, Med: -1.03, Max: 50.54
Current: -29.06
-64.49
50.54
ROC (Joel Greenblatt) % -86.23
ROC (Joel Greenblatt) ranked lower than
59.85% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
CEMI: -86.23
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -122.3, Med: -1.05, Max: 98.41
Current: -86.23
-122.3
98.41
3-Year Total Revenue Growth Rate 11.30
3-Year Revenue Growth Rate ranked lower than
84.62% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
CEMI: -2.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -15.45, Max: 26.3
Current: -2.8
0
26.3
3-Year Total EBITDA Growth Rate -45.60
3-Year EBITDA Growth Rate ranked lower than
100.00% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
CEMI: -27.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -30.10
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
CEMI: -30.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» CEMI's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CEMI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 325413    SIC : 2835
Compare OSTO:BOUL LSE:MXCT XKRX:180400 LSE:AGL OSTO:CRAD B AMEX:VNRX XKRX:153710 NAS:FLGT XKRX:253840 TSE:7707 LSE:RENX XKRX:229000 WAR:BKM XKRX:263690 TSE:4978 OCSE:BIOPOR NAS:TTOO OSL:GENT-ME XKRX:086040 NYSE:ENZ
Traded in other countries
Address 3661 Horseblock Road, Medford, NY, USA, 11763
Chembio Diagnostics Inc is a US-based company which develops, manufactures, and commercializes point-of-care diagnostic tests which detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. Most of the company's revenue comes from the sale of ASC 605.

Ratios

Current vs industry vs history
PB Ratio 3.25
PB Ratio ranked lower than
67.35% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
CEMI: 3.25
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.39, Med: 3.8, Max: 20.71
Current: 3.25
1.39
20.71
PS Ratio 2.62
PS Ratio ranked lower than
55.22% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
CEMI: 2.62
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.44, Med: 1.63, Max: 4.98
Current: 2.62
0.44
4.98
EV-to-EBIT -9.66
EV-to-EBIT ranked lower than
100.00% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
CEMI: -9.66
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -56.9, Med: -5.3, Max: 156.9
Current: -9.66
-56.9
156.9
EV-to-EBITDA -10.81
EV-to-EBITDA ranked lower than
100.00% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
CEMI: -10.81
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -553.2, Med: -6.35, Max: 42.9
Current: -10.81
-553.2
42.9
EV-to-Revenue 2.76
EV-to-Revenue ranked lower than
54.96% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
CEMI: 2.76
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 1.5, Max: 5.1
Current: 2.76
0.4
5.1
Current Ratio 3.73
Current Ratio ranked higher than
64.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
CEMI: 3.73
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 3.26, Max: 58
Current: 3.73
0.01
58
Quick Ratio 2.38
Quick Ratio ranked higher than
50.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
CEMI: 2.38
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 2.37, Max: 58
Current: 2.38
0.01
58
Days Inventory 118.49
Days Inventory ranked lower than
70.10% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
CEMI: 118.49
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 58.96, Med: 75.64, Max: 133.96
Current: 118.49
58.96
133.96
Days Sales Outstanding 82.87
Days Sales Outstanding ranked lower than
74.02% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
CEMI: 82.87
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 31.69, Med: 62.72, Max: 110.1
Current: 82.87
31.69
110.1
Days Payable 69.88
Days Payable ranked lower than
100.00% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
CEMI: 69.88
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 37.5, Med: 42.59, Max: 69.88
Current: 69.88
37.5
69.88

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -14.40
3-Year Share Buyback Rate ranked lower than
52.22% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
CEMI: -14.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -851, Med: -48.15, Max: 46.7
Current: -14.4
-851
46.7

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.48
Price-to-Tangible-Book ranked lower than
56.04% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
CEMI: 4.48
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.58, Med: 4.54, Max: 171.26
Current: 4.48
1.58
171.26
Price-to-Median-PS-Value 1.61
Price-to-Median-PS-Value ranked lower than
91.71% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
CEMI: 1.61
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.16, Med: 0.9, Max: 5.57
Current: 1.61
0.16
5.57
Earnings Yield (Joel Greenblatt) % -10.34
Earnings Yield (Greenblatt) ranked lower than
64.15% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
CEMI: -10.34
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -41.2, Med: -3.7, Max: 11.3
Current: -10.34
-41.2
11.3

More Statistics

Revenue (TTM) (Mil) $ 33.99
EPS (TTM) $ -0.65
Beta 1.88
Volatility % 58.52
52-Week Range $ 4.85 - 11.55
Shares Outstanding (Mil) 17.17

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 1
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N